Federal Working Group

T1International Federal Working Group Priorities

1) Win a federal price cap on insulin: Three companies, Eli Lilly, Novo Nordisk, and Sanofi, dominate more than 90% of the insulin market. This means that while production of insulin costs around $6 to manufacture, these three companies are charging around $300 for a single vial of insulin (most people need 2-4 vials per month). When a person is dependent on a drug to live, Big Pharma can increase their prices to whatever the market will bear. Capping the price of insulin at the pharmacy counter for anyone who needs it, regardless of insurance, will save lives as we work on more structural changes to lower the cost of insurance.

2) Patent reform: In 1923, the discoverers of insulin sold the patent for $1, saying “insulin does not belong to me, it belongs to the world”. Rather than the gift it was intended to be, their discovery has become the poster child for pharmaceutical price gouging. Over the last 100 years, while insulin has improved, even many of the newest insulins are decades old. Still, pharma has created ‘thickets’ of patents around them, allowing them to maintain a monopoly. This patent thicketing, along with pay-for-delay patent dispute settlement agreements, and more has hindered true competition and thus the lowering of drug prices. 

About the Federal Working Group

In 2021, T1International Chapter Advocates came together as a Federal Working Group to take action on the needs and concerns of people with diabetes at the US federal level. Together, these volunteer leaders from twelve states learn about federal-level actions that impact people with diabetes. They review and evaluate potential policy solutions for endorsement, and advocate for change. This advocacy includes holding meetings with policy-makers, getting media attention, and more. We recognize that none of these alone can achieve our vision, but together with state and global progress, we believe we can achieve insulin for all. 


For questions, to connect with the T1International Federal Working Group, or to support this work, please email T1International’s Policy Manager, Shaina Kasper at

For more information about T1International, visit this page

About T1International

T1International is a global type 1 diabetes advocacy organization led by people with type 1 diabetes for people with type 1 diabetes. T1International believes in a world where everyone with type 1 diabetes – no matter where they live – has everything they need to survive and achieve their dreams. The organization accepts no funding from pharmaceutical companies and provides advocacy training and support. In 2014 T1International launched the #insulin4all campaign, which has grown into a global movement.